Imatinib-induced fulminant liver failure in chronic myeloid leukemia: role of liver transplant and second-generation tyrosine kinase inhibitors: a case report.
J Med Case Rep
; 12(1): 63, 2018 Mar 10.
Article
en En
| MEDLINE
| ID: mdl-29523185
ABSTRACT
BACKGROUND:
There is a worldwide problem of acute liver failure and mortality associated with remaining on the waiting for a liver transplant. In this study, we highlight results published in recent years by leading transplant centers in evaluating imatinib-induced acute liver failure in chronic myeloid leukemia and follow-up in liver transplantation. CASE PRESENTATION A 36-year-old brown-skinned woman (mixed Brazilian race) diagnosed 1 year earlier with chronic myeloid leukemia was started after delivery of a baby and continued for 6 months with imatinib mesylate (selective inhibitor of Bcr-Abl tyrosine kinase), which induced liver failure. We conducted a literature review using the PubMed database for articles published through September 2017, and we demonstrate a role of liver transplant in this situation for imatinib-induced liver failure. We report previously published results and a successful liver transplant after acute liver failure due to imatinib-induced in chronic myeloid leukemia treatment.CONCLUSIONS:
We report a case of a successful liver transplant after acute liver failure resulting from imatinib-induced chronic myeloid leukemia treatment. The literature reveals the importance of prompt acute liver failure diagnosis and treatment with liver transplant in selected cases.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Leucemia Mielógena Crónica BCR-ABL Positiva
/
Trasplante de Hígado
/
Fallo Hepático Agudo
/
Inhibidores de Proteínas Quinasas
/
Enfermedad Hepática Inducida por Sustancias y Drogas
/
Mesilato de Imatinib
Límite:
Adult
/
Female
/
Humans
Idioma:
En
Revista:
J Med Case Rep
Año:
2018
Tipo del documento:
Article
País de afiliación:
Brasil